DRUG
NASDAQBright Minds Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$65.05-13.22 (-16.89%)
2026-03-052026-06-08
News · 26 weeks310%
2025-12-142026-06-07
Mix990d
- Other4(44%)
- SEC Filings3(33%)
- Analyst1(11%)
- Insider1(11%)
Latest news
25 items- SECSEC Form 6-K filed by Bright Minds Biosciences Inc.6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
- SECSEC Form 6-K filed by Bright Minds Biosciences Inc.6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
- SECSEC Form 6-K filed by Bright Minds Biosciences Inc.6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
- PRBright Minds Biosciences to Present at Jefferies Global Healthcare ConferenceNEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows: DATE:Wednesday, June 3, 2026TIME:4:20PM EDTWEBCAST:Click Here The live and archived webcast will be accessible from the Company's website at https://investors.brightmindsbio.com/news-events/presentations under Events and Presentation. The replay of the web
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
- INSIDERFormer 10% Owner Cormorant Asset Management, Lp sold $9,785,124 worth of shares (109,331 units at $89.50) (SEC Form 4)4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
- ANALYSTJefferies initiated coverage on Bright Minds Biosciences with a new price targetJefferies initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $145.00
- PRBright Minds Biosciences to Present at Upcoming ConferencesNEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT:TD Cowen 46th Annual Health Care ConferenceDATE:Wednesday, March 4, 2026TIME:9:10am ETWEBCAST:https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/cy8oQuZ2XnJiLiEqXopBn7 EVENT: Leerink Partners 2026 Global Healthcare ConferenceDATE: Monday, March 9, 2026WEBCAST:No
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
- SECSEC Form 6-K filed by Bright Minds Biosciences Inc.6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
- SECSEC Form 6-K filed by Bright Minds Biosciences Inc.6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
- PRBright Minds Biosciences Announces Closing of US$175 Million Public OfferingNEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the "Common Shares") at a price of US$90.00 per Common Share for gross proceeds of US$175,050,000 (the "Offering"). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities sold in this Offering were offered by Bright Minds. The Company intends to use the net proceeds
- SECSEC Form 6-K filed by Bright Minds Biosciences Inc.6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
- SECSEC Form 424B5 filed by Bright Minds Biosciences Inc.424B5 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
- SECSEC Form 6-K filed by Bright Minds Biosciences Inc.6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
- PRBright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common StockNEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces the pricing of its previously announced public offering of 1,945,000 common shares in the capital of the Company (the "Common Shares") at a price of $90.00 per Common Share for anticipated gross proceeds of $175,050,000 (the "Offering"). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities being sold in this Offering are being offered by Bright Minds. The closing
- SECSEC Form 6-K filed by Bright Minds Biosciences Inc.6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
- SECSEC Form FWP filed by Bright Minds Biosciences Inc.FWP - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
- SECSEC Form FWP filed by Bright Minds Biosciences Inc.FWP - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
- SECSEC Form 424B5 filed by Bright Minds Biosciences Inc.424B5 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
- SECSEC Form 6-K filed by Bright Minds Biosciences Inc.6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
DRUG FAQ
6 questionsWhat does Bright Minds Biosciences Inc. do?
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is...Where does DRUG stock trade?
Bright Minds Biosciences Inc. (DRUG) is listed on NASDAQ.What sector and industry is DRUG in?
Bright Minds Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about DRUG?
Bright Minds Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2026-04-13.What companies are similar to DRUG?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare DRUG side-by-side with any of them on Quantisnow.How can I track DRUG on Quantisnow?
Quantisnow aggregates Bright Minds Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DRUG to receive live email and push alerts on every new disclosure.